"We entered 2020 with a focused agenda for leveraging our Accordion Pill platform in both the near- and long-term, with goals to outlicence our late-stage Parkinson's disease program, to advance our ...
JERUSALEM, Nov. 12, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the three and nine months ended September 30, 2019.
* INTEC PHARMA - TOGETHER WITH NOVARTIS CO HAS AGREED TO PROCEED WITH ACCORDION PILL PROGRAM, PLANS TO ENTER CLINIC WITH A FIRST-IN-HUMAN PK STUDY IN FIRST HALF OF 2019 Source text for Eikon: Further ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback